WuXi AppTec Revenue Soars as Changing Government Policies Bring Headaches
The CXO giant announced it expects to post record-high revenue in the first quarter of 2022 Key takeaways: WuXi AppTec said it expects year-on-year revenue growth of 65% to 68%…
Newly Merged dMed-Clinipace Turns Up Heat in China’s Booming CRO Market
Company’s new $50 million funding is the first since its April merger, as competition grows among nation’s contract research organizations (CROs) Key points: dMed-Clinipace’s raises $50 million in the…
RELATED ARTICLES
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK -
BRIEF: WuXi AppTec sells advanced therapies units in U.K. and U.S.
2359.HK 603259.SHG
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
